Mirtazapine side effects: what 91,033 FDA adverse event reports show
Drug class
Not stated in label
Who reports
91,033 reports · 84% serious · 13,998 with death outcome · 58% female
Used for
Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults . Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults. (1)
What it is
Mirtazapine tablets contain mirtazapine, USP. Mirtazapine has a tetracyclic chemical structure and belongs to the piperazino-azepine group of compounds. It is designated 1,2,3,4,10,14b-hexahydro- 2-methylpyrazino [2,1-a] pyrido [2,3-c] [2] benzazepine and has the empirical formula of C 17 H 19 N 3 .
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] .
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,166 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Amaurosis fugax | 183 | 47.4 40.4–55.6ROR 47.5 · calibrated p 2e-5 ✓ | 39.2 EB05 34.7 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=183 · 100% clinician | not reported in cached trials |
| Delusion of grandeur | 72 | 44.0 34.2–56.7ROR 44.1 · calibrated p 4e-5 ✓ | 36.7 EB05 30.1 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=71 · ♀ 0% (drug 58%) · 100% clinician | not reported in cached trials |
| Anticholinergic syndrome | 165 | 26.5 22.6–31.1ROR 26.6 · calibrated p 5e-4 ✓ | 23.8 EB05 20.9 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=164 · ♀ 100% (drug 58%) · 100% clinician | not reported in cached trials |
| Cogwheel rigidity | 107 | 25.9 21.2–31.7ROR 26.0 · calibrated p 6e-4 ✓ | 23.3 EB05 19.8 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=107 · ♀ 100% (drug 58%) · 100% clinician | not reported in cached trials |
| Intrusive thoughts | 113 | 25.5 21.0–31.0ROR 25.6 · calibrated p 7e-4 ✓ | 23.0 EB05 19.6 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=112 · ♀ 0% (drug 58%) | not reported in cached trials |
| Depersonalisation/derealisation disorder | 135 | 21.0 17.6–25.1ROR 21.0 · calibrated p 0.002 ✓ | 19.3 EB05 16.7 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=133 | not reported in cached trials |
| Gastric ph decreased | 76 | 18.3 14.5–23.1ROR 18.3 · calibrated p 0.003 ✓ | 16.9 EB05 13.9 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=74 · ♀ 100% (drug 58%) · 100% clinician | not reported in cached trials |
| Serotonin syndrome | 1,332 | 17.2 16.3–18.2ROR 17.4 · calibrated p 0.004 ✓ | 16.0 EB05 15.3 · IC025 +3.9 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 14.8 · serious PRR 10.9 | not reported in cached trials |
| Systemic infection | 92 | 13.4 10.9–16.6ROR 13.4 · calibrated p 0.012 ✓ | 12.6 EB05 10.5 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=91 · 100% clinician | not reported in cached trials |
| Product monitoring error | 79 | 13.4 10.7–16.8ROR 13.4 · calibrated p 0.012 ✓ | 12.5 EB05 10.3 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | serious n=79 · 100% clinician | not reported in cached trials |
| Bezoar | 71 | 12.5 9.8–15.8ROR 12.5 · calibrated p 0.016 ✓ | 11.7 EB05 9.5 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=71 · ♀ 100% (drug 58%) · 100% clinician | not reported in cached trials |
| Derealisation | 107 | 12.1 9.9–14.7ROR 12.1 · calibrated p 0.017 ✓ | 11.4 EB05 9.6 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=104 · ♀ 100% (drug 58%) | not reported in cached trials |
| H1n1 influenza | 68 | 11.6 9.1–14.8ROR 11.6 · calibrated p 0.021 ✓ | 10.8 EB05 8.8 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=68 · ♀ 100% (drug 58%) · 100% clinician | NCT00535288: 2/158 (1.3%) on Mirtazapine; 15/314 (4.8%) control |
| Sopor | 642 | 11.6 10.7–12.5ROR 11.6 · calibrated p 0.019 ✓ | 11.0 EB05 10.3 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 8.6 · serious PRR 7.6 · 96% clinician | not reported in cached trials |
| Sleep paralysis | 70 | 11.5 9.1–14.6ROR 11.5 · calibrated p 0.021 ✓ | 10.8 EB05 8.7 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=66 · ♀ 100% (drug 58%) | not reported in cached trials |
| Poisoning deliberate | 438 | 11.3 10.3–12.5ROR 11.4 · calibrated p 0.021 ✓ | 10.8 EB05 10.0 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 7.4 · 100% clinician | not reported in cached trials |
| Intentional self-injury | 921 | 11.0 10.3–11.7ROR 11.1 · calibrated p 0.023 ✓ | 10.5 EB05 9.9 · IC025 +3.3 3/3 methods agree | Reporting / coding artifact | serious PRR 7.3 | not reported in cached trials |
| Urinary tract disorder | 205 | 11.0 9.5–12.6ROR 11.0 · calibrated p 0.024 ✓ | 10.4 EB05 9.2 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | serious n=204 · 100% clinician | not reported in cached trials |
| Accidental death | 83 | 10.8 8.6–13.4ROR 10.8 · calibrated p 0.027 ✓ | 10.1 EB05 8.3 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=83 · 100% clinician | not reported in cached trials |
| Suspected suicide | 210 | 10.6 9.2–12.1ROR 10.6 · calibrated p 0.027 ✓ | 10.1 EB05 8.9 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=210 · 100% clinician | not reported in cached trials |
| Multiple drug overdose intentional | 142 | 10.4 8.8–12.3ROR 10.5 · calibrated p 0.029 ✓ | 9.9 EB05 8.6 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=141 · 100% clinician | not reported in cached trials |
| Neuroleptic malignant syndrome | 515 | 10.4 9.5–11.3ROR 10.4 · calibrated p 0.028 ✓ | 9.9 EB05 9.2 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 8.8 · serious PRR 6.9 | not reported in cached trials |
| Noninfective gingivitis | 62 | 10.3 8.0–13.3ROR 10.3 · calibrated p 0.031 ✓ | 9.6 EB05 7.7 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=58 · ♀ 100% (drug 58%) · 100% consumer | not reported in cached trials |
| Hallucinations, mixed | 180 | 10.2 8.8–11.9ROR 10.3 · calibrated p 0.030 ✓ | 9.7 EB05 8.6 · IC025 +3.0 3/3 methods agree | Labeled (related wording) related wording | serious n=167 | not reported in cached trials |
| Hyperkinesia | 88 | 10.1 8.1–12.5ROR 10.1 · calibrated p 0.033 ✓ | 9.5 EB05 7.9 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=85 | not reported in cached trials |
| Depressive symptom | 144 | 9.8 8.3–11.6ROR 9.8 · calibrated p 0.036 ✓ | 9.3 EB05 8.1 · IC025 +2.9 3/3 methods agree | Labeled (related wording) related wording | serious n=141 | not reported in cached trials |
| Inappropriate antidiuretic hormone secretion | 415 | 9.7 8.8–10.8ROR 9.8 · calibrated p 0.035 ✓ | 9.3 EB05 8.6 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 6.4 · 94% clinician | not reported in cached trials |
| Psychomotor retardation | 111 | 9.5 7.9–11.5ROR 9.5 · calibrated p 0.040 ✓ | 9.0 EB05 7.6 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=111 · 100% clinician | not reported in cached trials |
| Major depression | 290 | 9.5 8.4–10.6ROR 9.5 · calibrated p 0.039 ✓ | 9.0 EB05 8.2 · IC025 +3.0 3/3 methods agree | Labeled (related wording) related wording | serious PRR 6.4 | not reported in cached trials |
| Wrong patient received product | 113 | 9.4 7.8–11.4ROR 9.4 · calibrated p 0.041 ✓ | 8.9 EB05 7.6 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | serious n=113 · 100% clinician | not reported in cached trials |
| Illusion | 66 | 9.4 7.4–12.1ROR 9.4 · calibrated p 0.042 ✓ | 8.8 EB05 7.1 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=62 · ♀ 0% (drug 58%) | not reported in cached trials |
| Coma scale abnormal | 110 | 9.2 7.6–11.1ROR 9.2 · calibrated p 0.045 ✓ | 8.7 EB05 7.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=110 · 100% clinician | not reported in cached trials |
| Jc virus infection | 61 | 9.1 7.0–11.8ROR 9.1 · calibrated p 0.047 ✓ | 8.4 EB05 6.8 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=61 · ♀ 0% (drug 58%) · 100% clinician | not reported in cached trials |
| Feeling of despair | 174 | 8.9 7.7–10.4ROR 8.9 · calibrated p 0.048 ✓ | 8.5 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=169 | not reported in cached trials |
| Anxiety disorder | 125 | 8.9 7.4–10.6ROR 8.9 · calibrated p 0.050 ✓ | 8.4 EB05 7.2 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious n=123 | not reported in cached trials |
| Stoma site erythema | 69 | 8.8 6.9–11.2ROR 8.8 · calibrated p 0.053 | 8.2 EB05 6.6 · IC025 +2.6 3/3 methods agree | Labeled (related wording) related wording | serious n=60 · ♀ 0% (drug 58%) · 100% consumer | not reported in cached trials |
| Bradykinesia | 214 | 8.7 7.6–10.0ROR 8.8 · calibrated p 0.051 | 8.4 EB05 7.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=196 | not reported in cached trials |
| Akathisia (inner restlessness) | 487 | 8.5 7.8–9.3ROR 8.5 · calibrated p 0.055 | 8.2 EB05 7.6 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.3 | not reported in cached trials |
| Cleft palate | 69 | 8.5 6.7–10.8ROR 8.5 · calibrated p 0.059 | 7.9 EB05 6.4 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=69 · 100% clinician | not reported in cached trials |
| Muscle rigidity | 426 | 8.5 7.7–9.3ROR 8.5 · calibrated p 0.055 | 8.2 EB05 7.5 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | age-adj. PRR 7.4 · serious PRR 6.1 | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Suicidality | 7,062 | 6.86.6–6.9 | signal |
| Extrapyramidal | 2,532 | 5.65.4–5.9 | signal |
| Hyponatraemia | 1,921 | 5.65.4–5.9 | signal |
| Depression | 4,166 | 3.43.3–3.6 | signal |
| Rhabdomyolysis / myopathy | 1,084 | 3.12.9–3.3 | signal |
| Fall / fracture | 4,380 | 2.72.6–2.7 | signal |
| Arrhythmia / qt | 2,188 | 2.62.5–2.7 | signal |
| Seizure | 2,073 | 2.42.3–2.6 | signal |
| Pancreatitis | 701 | 2.01.9–2.2 | raised |
| Gi bleeding | 1,494 | 1.91.8–2.0 | raised |
| Kidney injury | 3,545 | 1.81.7–1.9 | raised |
| Serious infection | 5,218 | 1.61.5–1.6 | raised |
| Anaemia | 1,960 | 1.51.4–1.6 | raised |
| Severe cutaneous reaction | 484 | 1.51.4–1.6 | raised |
| Liver injury | 1,924 | 1.51.4–1.5 | raised |
| Venous thromboembolism | 1,335 | 1.41.3–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Mirtazapine as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (1 of 40 signal terms matched).
- NCT00535288 — Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (17 (N=946, PHASE3; 21 AE terms posted; arms: Placebo; Esmirtazapine 2.25 mg; Esmertazapine 4.5 mg; Esmirtazapine 9 mg)
- NCT00560833 — Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (461 (N=943, PHASE3; 22 AE terms posted; arms: Placebo; Esmirtazapine 2.25 mg; Esmirtazapine 4.5 mg; Esmirtazapine 9 mg)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Nausea | 5,028 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.640 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.6 | NCT00560833: 5/155 (3.2%) on Mirtazapine; 17/317 (5.4%) control |
| Fatigue (tiredness) | 4,904 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.630 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.5 | NCT00535288: 23/158 (14.6%) on Mirtazapine; 9/314 (2.9%) control |
| Drug ineffective (drug did not work) | 4,786 | 0.8 0.8–0.9ROR 0.8 · calibrated p 0.199 | 0.8 EB05 0.8 · IC025 -0.3 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.2 | not reported in cached trials |
| Fall | 4,168 | 2.9 2.8–3.0ROR 3.0 · calibrated p 0.625 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.3 · serious PRR 2.3 | not reported in cached trials |
| Diarrhoea (diarrhea) | 4,111 | 1.5 1.4–1.5ROR 1.5 · calibrated p 0.640 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.4 | not reported in cached trials |
| Off label use (used outside approved label) | 3,998 | 1.1 1.0–1.1ROR 1.1 · calibrated p 0.349 | 1.1 EB05 1.0 · IC025 +0.0 | Reporting / coding artifact | age-adj. PRR 1.0 · serious PRR 1.1 | not reported in cached trials |
| Toxicity to various agents | 3,836 | 5.4 5.2–5.5ROR 5.6 · calibrated p 0.182 | 5.3 EB05 5.1 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 5.0 · serious PRR 3.7 · 92% clinician | not reported in cached trials |
| Dizziness | 3,585 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.763 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.7 | NCT00535288: 13/158 (8.2%) on Mirtazapine; 12/314 (3.8%) control |
| Anxiety | 3,579 | 2.9 2.8–3.0ROR 3.0 · calibrated p 0.629 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.8 · serious PRR 2.5 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 3,537 | 1.4 1.4–1.5ROR 1.5 · calibrated p 0.616 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.1 · serious PRR 1.2 | not reported in cached trials |
| Death | 3,450 | 0.9 0.9–1.0ROR 0.9 · calibrated p 0.255 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Outcome field, not a reaction | age-adj. PRR 1.0 · serious PRR 0.6 | not reported in cached trials |
| Drug interaction | 3,345 | 4.9 4.8–5.1ROR 5.1 · calibrated p 0.225 | 4.9 EB05 4.7 · IC025 +2.2 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.8 · serious PRR 3.6 | not reported in cached trials |
| Vomiting | 3,317 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.743 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.5 | not reported in cached trials |
| Depression | 3,296 | 3.4 3.2–3.5ROR 3.4 · calibrated p 0.499 | 3.3 EB05 3.2 · IC025 +1.7 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 3.0 · serious PRR 2.8 | not reported in cached trials |
| Headache | 3,158 | 1.2 1.1–1.2ROR 1.2 · calibrated p 0.418 | 1.2 EB05 1.1 · IC025 +0.2 | Labeled adverse reaction exact term | age-adj. PRR 1.0 · serious PRR 1.3 | NCT00535288: 13/158 (8.2%) on Mirtazapine; 33/314 (10.5%) control |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Amaurosis fugax — n=183, PRR 47.4
- Delusion of grandeur — n=72, PRR 44.0
- Anticholinergic syndrome — n=165, PRR 26.5
- Cogwheel rigidity — n=107, PRR 25.9
- Intrusive thoughts — n=113, PRR 25.5
- Depersonalisation/derealisation disorder — n=135, PRR 21.0
- Bezoar — n=71, PRR 12.5
- Derealisation — n=107, PRR 12.1
- H1n1 influenza — n=68, PRR 11.6 (also seen in trial arm)
- Sopor — n=642, PRR 11.6
✓ A hand-written Bradford Hill causality assessment exists for this drug: Mirtazapine ↔ Suicidal Ideation.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Mirtazapine?
In FDA FAERS, the most frequently co-reported reaction terms for Mirtazapine are nausea, fatigue, fall, diarrhoea, toxicity to various agents, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Mirtazapine have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] .
Do FAERS signals prove that Mirtazapine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 1ba111d1-cf92-4cd9-afcb-3bebd1bacd46, effective 20230828; matched on
openfda.generic_name.exact:"MIRTAZAPINE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,206 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
MIRTAZAPINE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.